肖珍珍,李惠勉

• 1:郑州大学第二附属医院

摘要(Abstract)：

目的探讨舒洛地特对大鼠脑缺血再灌注后脑组织的保护作用及机制。方法将72只Wistar大鼠随机分为3组即假手术组、模型组、舒洛地特干预组,采用改良Zea Longa[1]线栓法制备大鼠大脑中动脉局灶性脑缺血模型,应用免疫组化法检测肿瘤坏死因子-а(TNF-а)及C-反应蛋白(CRP)的表达。结果大鼠局灶性脑缺血再灌注后缺血脑组织中TNF-a及CRP含量增加(P<0.01)。与模型组相比较,舒洛地特组TNF-a及CRP的含量减少,脑组织肿胀减轻,死亡神经元明显减少,神经功能缺损评分降低(P<0.05)。结论舒洛地特对大鼠脑缺血再灌注损伤有一定的保护作用,其机制可能是多方面的。

关键词(KeyWords)： 脑缺血再灌注;舒洛地特;肿瘤坏死因子;C-反应蛋白

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 肖珍珍,李惠勉

参考文献(References)：

• [1]Longa EZ,Weinstein PR,Carlson S,et al.Reversible middlecerebral artery occlusion without craniotomy in rats[J].Stroke,1989,20(1):84-91.
• [2]Hawkins BT,Davis TP.The blood-brain barrier/neurovascu-lar unit in health and disease[J].Pharmacol Rev,2005,57(2):173-185.
• [3]杨家丹,董志.脑缺血再灌注损伤的病因学研究进展[J].中国康复医学杂志,2006,21(10):935-938.
• [4]Huang J,Upadhyay UM,Tamargo RJ.Inflammation in strokeand focal cerebral ischemia[J].Surg Neurol,2006,66(3):232-245.
• [5]Ohtaki H,Yin L,Nakamachi Tet al.Expression of tumor nec-rosis factor alpha in nerver fibers and oligodendricytes aftertransient focal ischemia in mice[J].Neurosci Lett,2004,368:162-166.
• [6]Muri KW,Weir CJ,Awan W,et al.C-reactive protein and out-come after ischemic stroke[J].Stroke,2004,30(5):981-985.
• [7]Lavine SD,Hof man FM,Zlokovic BV.Circulation antibody a-gainst tumor necrosis factor-a protects rat brain fromreperfu-sioninjury[J].Cereb Blood Flow Metab,1998,18(1):52-58.
• [8]Lauver DA,Lucchesi BR.Sulodexide:A renewed interest inthis Glycosaminoglycan[J].Lucchesi Cardiovascular Drug Re-views,2006,24,(3/4):214-226.
• [9]MiriamBarbanti,Stefano Guizzardi,Fiorella Calanni,et al.Anfithrombotic andthrombolytic activity of sulodexideinrats[J].Int J ClinLab Res,1992,(22):179-184.
• [10]徐海平,郑红光.舒洛地特对糖尿病大鼠肾脏转化生子因子β1与结缔组织生长因子表达的影响[J].中国老年医学杂志,2009,29,(12):1 498-1 500.
• [11]Parnetti L,Mari D,Abate G,et al.Vascular dementia italiansulodexide study(VADISs)clinical and biological results[J].Thromb Res,1997,87(2):225.
• [12]Lauver DA,Booth EA,White AJ,et al.Sulodexide attenuatesmyocardial ischemia/reperfusion injury and the deposition ofC-reactive protein in areas of infarction without affecting he-mostasis[J].Pharmacol Exp Ther,2005,312(2):794-800.